DEF: Artelo Biosciences Schedules 2025 Annual Meeting Amid Losses

Artelo Biosciences announces its 2025 Annual Meeting to elect directors and vote on executive compensation, following a year of continued net losses and declining shareholder returns.

Summary

• Artelo Biosciences, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Wednesday, December 31, 2025, at 8:00 a.m. Pacific Time.
• Stockholders will vote on the election of two Class II director nominees, Douglas Blayney, M.D., and Connie Matsui, to serve until the 2028 Annual Meeting.
• An advisory vote will be held on the compensation of the named executive officers, as disclosed in the 2024 Summary Compensation Table.
• The record date for stockholders entitled to vote at the Annual Meeting is December 10, 2025, with 2,018,746 shares of common stock outstanding.
• A 1-for-6 reverse stock split of common stock was effected on June 13, 2025.
• The company reported a GAAP Net Loss of ($9,826) thousand for 2024, ($9,829) thousand for 2023, and ($10,083) thousand for 2022.
• Total Stockholder Return for an initial $100 investment declined from $37.12 in 2022 to $13.62 in 2024.
• Gregory D. Gorgas's total compensation for 2024 was $1,060,470, with Compensation Actually Paid at $879,831.
• In February 2024, certain underwater options, including those held by the named executive officer and non-employee directors, were repriced to $9.30 per share and had their vesting schedules modified.
• Mark Spring was appointed Chief Financial Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer effective November 1, 2025, replacing Gregory D. Gorgas in these roles.
• The company entered into May 2025 and October 2025 Private Placements, issuing convertible notes and warrants, with directors and officers participating in these offerings.

Sentiment

Score: 2

Explanation: The sentiment is largely negative due to persistent net losses, a significant decline in Total Stockholder Return, a reverse stock split, and executive compensation practices (option repricing, increased severance) that appear misaligned with shareholder interests given the company's poor financial performance. While there are routine governance updates and a new CFO, the underlying financial health and compensation decisions overshadow these.

Positives

• The company has a structured corporate governance framework with a majority of independent directors and separate CEO and Board Chair roles.
• The Board's committees (Audit, Compensation, Corporate Governance and Nominating) are composed entirely of independent directors, with an audit committee financial expert identified.
• The adoption of a Compensation Recovery Policy (Clawback Policy) aligns with new SEC rules and good governance practices.
• The appointment of Mark Spring as Chief Financial Officer brings 30 years of life sciences financial leadership experience to the company.

Negatives

• The company reported consistent GAAP Net Losses of ($9,826) thousand in 2024, ($9,829) thousand in 2023, and ($10,083) thousand in 2022.
• Total Stockholder Return (TSR) has significantly declined, with an initial $100 investment falling to $13.62 by 2024 from $37.12 in 2022.
• A 1-for-6 reverse stock split was implemented in June 2025, often indicative of a struggling stock price and an attempt to meet listing requirements.
• Executive compensation for the CEO, Gregory D. Gorgas, was over $1 million in 2024, despite the company's substantial net losses and declining TSR.
• Underwater options held by executives and non-employee directors were repriced to a lower exercise price of $9.30 in February 2024, which can be viewed negatively by shareholders.
• The CEO's severance benefits were significantly increased in October 2025, raising cash severance from 12 to 24 months (up to 36 months with change of control) and COBRA reimbursements from 12 to 24 months (up to 36 months with change of control), which may be perceived as excessive given the company's performance.
• Mark Spring, the new Chief Financial Officer, filed a required Section 16(a) Form 3 late in connection with his appointment.

Risks

• The company's continued net losses and declining Total Stockholder Return indicate significant financial and operational challenges.
• The 1-for-6 reverse stock split suggests a risk of delisting or inability to maintain a sufficient stock price.
• Executive compensation practices, including option repricing and increased severance, may lead to shareholder dissatisfaction and potential governance concerns.
• The indemnification of directors and officers for liabilities under the Securities Act is, in the SEC's opinion, against public policy and unenforceable, posing a potential risk for directors and officers.
• If any director nominee is unable or unwilling to serve, proxies may vote for a substitute nominee or leave a vacancy, which the Board may fill or reduce its size, potentially impacting board composition.

Future Outlook

The filing primarily focuses on past performance, corporate governance, and upcoming stockholder votes. It does not provide explicit forward-looking financial guidance or strategic outlook beyond the operational details of the annual meeting and the vesting schedules of equity awards. The company's compensation committee aims to retain and incentivize key contributors while preserving cash resources and avoiding significant stock dilution, suggesting a focus on talent retention and capital efficiency for future operations.

Management Comments

• The Board of Directors has fixed the close of business on December 10, 2025, as the record date for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting.
• We are embracing technology to provide expanded access, improved communication, reduced environmental impact and cost savings for our stockholders and the Company by hosting a virtual meeting.
• Our management and Board were not aware of any other matters to be presented at the Annual Meeting as of the date of this proxy statement.
• The Compensation Committee determined that the Repricing and Revesting Amendment was in the best interests of the Company and its stockholders and provides the most effective means of retaining and incentivizing the Company's key contributors while preserving cash resources and without incurring stock dilution from significant additional equity grants.
• The Compensation Committee believes in a pay-for-performance philosophy for our NEO, and that a substantial portion of the overall compensation package for our executive officer should be variable and tied to the achievement of the objectives set by our board of directors each year.

Industry Context

Artelo Biosciences operates in the biopharmaceutical industry, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The company's consistent net losses and declining Total Stockholder Return suggest it is facing challenges common to early-stage or development-stage biotech companies, such as difficulties in achieving profitability or advancing pipeline assets. The use of convertible notes and warrants in private placements is a common financing mechanism for such companies to raise capital, often involving existing investors, including management and directors. The reverse stock split indicates a need to maintain compliance with exchange listing standards, a situation many smaller biotechs encounter when their stock price falls below minimum thresholds.

Comparison to Industry Standards

• The company's consistent net losses and declining Total Stockholder Return (TSR) significantly underperform the broader biotechnology industry, which, while volatile, often sees periods of substantial growth for successful development-stage companies.
• The 1-for-6 reverse stock split is a measure typically taken by companies with severely depressed stock prices, contrasting with industry leaders who maintain robust valuations.
• Executive compensation levels, particularly the CEO's over $1 million total compensation in 2024, appear high when compared to the company's negative financial performance (net loss of nearly $10 million) and drastic decline in TSR, suggesting a potential misalignment with shareholder value creation that is often scrutinized against industry best practices.
• The repricing of underwater stock options, while a mechanism to re-incentivize, is generally viewed unfavorably by institutional investors and governance watchdogs as it effectively grants a 'do-over' for management at shareholder expense, a practice less common among high-performing industry peers.
• The increase in CEO severance benefits, especially amidst poor financial results, deviates from a 'pay-for-performance' standard often sought by investors in the biotech sector, where executive payouts are typically more closely tied to achieving clinical or commercial milestones and positive financial outcomes.

Management Changes

Corporate Governance

Legal Proceedings

• No current legal proceedings material to the evaluation of directors or executive officers are disclosed, nor have there been any during the past ten years.

Related Party Transactions

• In the May 2025 Private Placement, Director Connie Matsui purchased $140,000 in convertible notes, Director Tamara Favorito purchased $25,000, and Director/Officer Gregory Gorgas purchased $35,000. These notes later converted into warrants.
• In the October 2025 Private Placement, Director Connie Matsui purchased $110,842.52 in convertible notes and 70,376 warrants, Director Tamara Favorito purchased $19,792.93 in convertible notes and 12,566 warrants, and Director/Officer Gregory Gorgas purchased $27,710.36 in convertible notes and 17,592 warrants.
• On October 15, 2025, the company entered into a cooperation letter agreement with Daniel S. Farb and affiliates, where Mr. Farb agreed to withdraw director nominations and the Farb Parties agreed to standstill restrictions and voting commitments, including voting in favor of Board-nominated directors and against removal proposals.

Stakeholder Impact

• **Shareholders**: Will be impacted by the outcome of director elections and the advisory vote on executive compensation. The reverse stock split and declining TSR have negatively impacted shareholder value. The private placements involving directors and officers could raise questions about dilution and fairness.
• **Employees**: The repricing of underwater options and the new stock option grants aim to retain and incentivize key contributors, which could positively impact employee morale and retention.
• **Management/Directors**: Directly impacted by the proposed director elections, executive compensation decisions, and the terms of their employment agreements and equity awards. Their participation in private placements indicates continued investment in the company.

Next Steps

• Stockholders must register online by December 30, 2025, at 11:59 PM ET to attend the virtual Annual Meeting.
• Stockholders are encouraged to vote their shares via internet, telephone, or mail prior to the Annual Meeting, or during the meeting itself.
• The company will file a Current Report on Form 8-K with the SEC within four business days of the Annual Meeting to report preliminary voting results, with an amendment for final results if necessary.
• Stockholders wishing to submit proposals for the 2026 annual meeting must do so by August 13, 2026 (Rule 14a-8) or provide advance notice between September 2, 2026, and October 2, 2026 (bylaws).

Key Dates

Recommendation

The company's financial performance is severely concerning, marked by consistent net losses and a drastic decline in Total Stockholder Return over the past three years. The 1-for-6 reverse stock split is a clear indicator of significant stock price weakness. Executive compensation practices, including the repricing of underwater options and substantial increases in CEO severance benefits, appear misaligned with shareholder interests given the company's poor financial health. While the company is addressing routine governance matters, the fundamental financial trajectory and compensation decisions present a high-risk profile with limited upside potential for investors. The related party transactions, while common, do not offset the broader financial distress.

Keywords

Artelo Biosciences, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Say-on-Pay, Reverse Stock Split, Corporate Governance, Biotechnology, SEC Filing, Financial Performance, Stockholder Return, Capital Raise, Convertible Notes, Warrants